Consistently, the percentage of SA-β-galactosidase positive LAM/TSC cells was reduced by rapamycin treatment (Figure 3c) as well as the percentage of cells expressing the phosphorylated histone H2A.X analysed by flow cytometry (3.04% and 1.95% for LAM/TSC cells treated with 0.5 ng/mL and 1 ng/mL of rapamycin, respectively, and 7.8% in control LAM/TSC cells) (data not shown). The gene discussed is TSC2; the disease is lymphangioleiomyomatosis.